Sarepta

U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve’s interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31, while the S&P 500 lost nearly 1.1% to 5,614.66. The Nasdaq tumbled 1.7% to 17,504.12. These are the top stocks that...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared by more than 10 percent Wednesday after the company reported encouraging results from a clinical trial of a therapy intended to treat Duchenne muscular dystrophy (DMD). Sarepta's drug called golodirsen showed that patients who suffer from...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a smid-cap biopharmaceutical company that focuses on the treatment of rare neuromuscular diseases including Duchenne muscular dystrophy, saw its stock peak north of $60 per share in late 2016 after the U.S. Food and Drug Administration green-lighted its DMD...

Sarepta Therapeutics Inc's (NYSE: SRPT) rough Tuesday carried over into Wednesday's session after the company reported a better than expected loss in its fourth quarter but expects full year sales of Exondys to fall short of what analysts were expecting. Brian Skorney of Baird commented in...

It has been more than three decades since the U.S. Congress passed a bill encouraging pharmaceutical companies to develop new drugs to treat rare diseases. According to NPR, President Ronald Reagan's Orphan Drug Act of 1983 resulted in more than 200 companies introducing 450 orphan drugs to the...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by more than 24 percent Tuesday. The catalyst for the move appears to be the company's 10:30 a.m. presentation at the JPMorgan Healthcare Conference, followed by an encouraging report by TheStreet's Adam Feuerstein. As...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared as high as $63.73 following a controversial decision by the U.S. Food and Drug Administration to approve the company's treatment of Duchenne muscular dystrophy in September 2016. Since the FDA's announcement, the stock has lost more than half...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared more than 80 percent higher on Friday. The company confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called Translarna (ataluren...

Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the company's therapy for the treatment of Duchenne muscular dystrophy (DMD). There are three reasons investors should take a "more cautious view" on...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) fell about 5 percent Friday after Anthem Blue Cross said the clinical benefit of treatment for DMD (Duchenne Muscular Dystrophy) with the company's eteplirsen (Exondys 51), including improved motor function, has "not been demonstrated....

Sarepta Therapeutics Inc (NASDAQ: SRPT) forged a deal with Summit Therapeutics PLC (ADR) (NASDAQ: SMMT) to develop its utrophin pipeline in exchange for European rights and a Latin America option. Summit's stock soared higher by more than 100 percent following the announcement, but analysts...

Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared higher by more than 80 percent Monday and hit a new 52-week high of $56.18. Traders turned uber-bullish on the stock after the U.S. Food and Drug Administration granted an accelerated approval for its Duchenne Muscular Dystrophy (DMD) drug...